PMID: 42535667

Early changes in renal function do not appear to mediate cardiovascular risk with dapagliflozin plus semaglutide: a real-world observational hypothesis-generating cohort study.

AlTaweel Muneera O, Al Makhloof Saleh, AlKhayyal Ahmad K, Alrashada Jawaher, AlOhaymid Munirah, Alshahrani Abdullah, Alarfaj Abdullatif W, Alqarni Turki A, Al Moaibed Ghusoon, Altharman Noor M

Expert review of cardiovascular therapy · 2026

pp. 1-8

This entry links to third-party literature. For research use only.